Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2680-2685

  Morowitz, Michael J ^a,b   Barr, Rosalind ^a   Wang, Qun ^a   King, Rebecca ^a   Rhodin, Nicholas ^a   Pawel, Bruce ^a,b   Zhao, Huaqing ^a   Erickson, Scott A ^c   Sheppard, George S ^c   Wang, Jieyi ^c   Maris, John M ^a,b   Shusterman, Suzanne ^a,b,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ABBOTT LABORATORIES   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 357300; CYCLOPHOSPHAMIDE; ENZYME INHIBITOR; METHIONYL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC ENGINEERING; GROWTH RATE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; XENOGRAFT;

AMINOPEPTIDASES; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLOROBENZENES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED STRAINS; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20244370722     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1917     Document Type: Article

References (48)

1. Maris JM, Shusterman S. Neuroblastoma. In: Holland JF, Frei E, editors. Cancer medicine. Hamilton (Ontario, Canada): B.C. Decker, Inc.; 2003. p. 2263-376.
2. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: J.B. Lippincott Company; 2002. p. 895-938.
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
4. Meadows AT, Tsunematsu Y. Late effects of treatment for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier Science B.V.; 2000. p. 561-70.
5. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-Myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
6. Rossler J, Breit S, Havers W, Schweigerer L. Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia. Int J Cancer 1999;81:113-7.
7. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumorstage in human neuroblastomas. Clin Cancer Res 2000;6: 1900-8.
8. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins α(í)β3 and α(v)β5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000;60:712-21.
9. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 2000;34:386-93.
10. Hatzi E, Murphy C, Zoephel A, et al. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene 2002;21: 3552-61.
11. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310.
12. Wassberg E, Pahlman S, Westlin J, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997;41:327-33.
13. Katzenstein HM, Rademaker AW, Senger C, et al. Effectiveness of the angiogenesis inhibitorTNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5:4273-8.
14. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [see comments]. J Clin Invest 2000; 105:R15-24.
15. Davidoff AM, Leary MA, Ng CY, Vanin EF. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001;36: 30-6.
16. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001;7:977-84.
17. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002;99:11399-404.
18. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: the U.S. experience. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier Science B.V.; 2000. p. 417-36.
19. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 1997; 94:6099-103.
20. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000;77:465-73.
21. Nagabuchi E, VanderKolk WE, Une Y, Ziegler MM. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997;32:287-93.
22. Yoshizawa J, Mizuno R, Yoshida T, et al. Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. J Surg Res 2000;93:82-7.
23. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-5.
24. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-203.
25. Wang J, Sheppard GS, Lou P, et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 2003;63: 7861-9.
26. Wang J, Sheppard GS, Lou P, et al. Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. Biochemistry 2003;42: 5035-42.
27. Sheppard GS, Wang J, Kawai M, et al. 3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2. Bioorg Med Chem Lett 2004;14:865-8.
28. Morowitz M, Shusterman S, Mosse Y, et al. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol 2003;16:1248-56.
29. Schlesinger HR, Gerson JM, Moorhead PS, Maguire H, Hummeler K. Establishment and characterization of human neuroblastoma cell lines. Cancer Res 1976;36: 3094-100.
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
31. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16: 2985-95.
32. Weiss WA, Godfrey T, Francisco C, Bishop JM. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000;60: 2483-7.
33. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-74.
34. Endo H, Takenaga K, Kanno T, Satoh H, Mori S. Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4. J Biol Chem 2002;277:26396-402.
35. Bradshaw RA, Brickey WW, Walker KW. N-terminal processing: the methionine aminopeptidase and N-α-acetyl transferase families. Trends Biochem Sci 1998;23:263-7.
36. Ray MK, Datta B, Chakraborty A, Chattopadhyay A, Meza-Keuthen S, Gupta NK. The eukaryotic initiation factor 2-associated 67-kDa polypeptide (p67) plays a critical role in regulation of protein synthesis initiation in animal cells. Proc Natl Acad Sci U S A 1992; 89:539-43.
37. Datta B, Ray MK, Chakrabarti D, Wylie DE, Gupta NK. Glycosylation of eukaryotic peptide chain initiation factor 2 (elF-2)-associated 67-kDa polypeptide (p67) and its possible role in the inhibition of elF-2 kinase-catalyzed phosphorylation of the elF-2 α-subunit. J Biol Chem 1989;264:20620-4.
38. Dummitt B, Micka WS, Chang YH. N-terminal methionine removal and methionine metabolism in Saccharomyces cerevisiae. J Cell Biochem 2003;89:964-74.
39. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001;159:721-31.
40. Kanno T, Endo H, Takeuchi K, Morishita Y, Fukayama M, Mori S. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest 2002;82:893-901.
41. Matsuzawa T, Hatsugai M, Moriguchi K. Increase of methionine aminopeptidase activity in hyperplastic Leydig cells of rat cryptorchid testis: a histochemical study. J Vet Med Sci 1992;54: 1157-63.
42. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci U S A 2000;97:6427-32.
43. Kim S, La Montagne K, Sabio M, et al. Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides. Cancer Res 2004;64:2984-7.
44. Offodile R, Walton T, Lee M, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 1999;85:51-3.
45. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-5.
46. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998; 338:991-2.
47. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 1996;77: 1736-40.
48. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994;29: 1162-5; discussion 5-6.